Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lower gastro-intestinal cancers

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

Researchers reveal imaging technology could help diagnose and treat bowel cancer

Affecting over 250,000 people, bowel cancer is the fourth most common cancer in the UK

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

UK national study supports whole genome sequencing in standard cancer care

The trial combined data from the UK’s 100,000 Genomes Project and NHS records

- PMLiVE

Landmark UK medicines deal to save NHS £14bn in medicine costs

The agreement will help provide lifesaving treatments and care for NHS patients

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

Alzheimer’s Society raises concerns over undiagnosed young-onset dementia cases

The UK charity estimates that over 19,000 people in England are living without a diagnosis

- PMLiVE

NHS bookings for COVID-19 vaccinations open as winter programme starts early

Millions of people in England are now eligible to receive flu and COVID-19 vaccines

- PMLiVE

NHS England winter flu and COVID-19 vaccine programmes start early

Those who are eligible will be offered a vaccination from 18 September 2023 onwards

- PMLiVE

NHS England expands its shingles and HPV vaccination programmes

Around 900,000 more people will become eligible for a shingles vaccination

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

NHS England to offer world-first seven-minute cancer treatment injection

Subcutaneous administration of Roche’s Tecentriq could cut treatment time by up to 75%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links